SCHEMBL3083670

SCHEMBL3083670

COc1ccc(-c2ccc(N)c(C3=CCC(C)(C)CC3)c2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.55
FYN P06241 1/20 0.44
PIK3CA P42336 3/20 0.42
PIK3CD O00329 1/20 0.42
PIP5K1C O60331 1/20 0.42
PIK3CB P42338 1/20 0.42
PI4KA P42356 1/20 0.42
PIK3CG P48736 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
CYP2A6 P11509 2/20 0.40
KCNH2 Q12809 5/20 0.40
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
JAK2 O60674 1/20 0.37
PDGFRB P09619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083959 0.85 CSF1R (0.57) CSF1RFYNHSD17B1HSD17B2KCNH2
SCHEMBL18985672 0.73 PIK3CA (0.56) FYNPIK3CAPIK3CDPIP5K1CPIK3CB
SCHEMBL3089560 0.71 CYP2C8 (0.38) CSF1R
SCHEMBL31263364 0.71 IDO1 (0.39) CSF1R
SCHEMBL3078815 0.71 IDO1 (0.39) CSF1R
SCHEMBL3168410 0.71 TBK1 (0.39) PIK3CAPIK3CDPIK3CBPIK3CGKCNH2
SCHEMBL4848346 0.70 ALDH1A1 (0.42)
SCHEMBL24195783 0.69 ERN1 (0.53) FYNPIK3CAPIK3CDPIP5K1CPIK3CB
SCHEMBL3082554 0.69 PIK3CA (0.52) FYNPIK3CAPIK3CDPIP5K1CPIK3CB
SCHEMBL12492276 0.69 ALDH1A1 (0.53) FYNPIK3CAPIK3CDPIP5K1CPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885FYN 14/4885PIK3CA 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.